Santhera's AGAMREE (vamorolone) selected for South Korea accelerated reimbursement pilot program

Santhera Pharmaceuticals' lead product AGAMREE (vamorolone) has been selected for a South Korean pilot program aimed at improving timely access to medicines for patients with serious rare diseases. The 2026 program uses an accelerated reimbursement system where predefined contractual terms replace conventional price negotiations.

Detected & updated continuously · Source: Nebula